Email not displaying correctly? View it in your browser.
   Volume 3, Issue 3, September 2014
Follow us:   Facebook icon Twitter icon Youtube icon  
Robert B. Diasio, M.D Director's message: Cancer advocates are critical to research

Advocates ensure that the patient voice is represented in discussions about research.



Mayo Clinic launches 50-gene cancer panel test
A new test scans genes for mutations that help physicians customize cancer therapy.


Study shows virotherapy promising against multiple myeloma
Mayo Clinic documents case of a patient with complete remission after virus administration.


Lymph node ultrasounds more accurate in obese breast cancer patients
Study finds that axillary ultrasound is helpful regardless of a patient's weight.


Test of dual HER2 drugs finds trastuzumab alone remains gold standard
A combination of lapatinib, trastuzumab and chemotherapy doesn't improve patient outcome.


Chemo after radiation improves survival in adults with brain cancer
Patients who received chemo plus radiation had better outcomes than those who had radiation alone.


Molecular sequencing in ovarian cancer may predict response to bevacizumab
Gene sequencing can identify patients who are most likely to respond to an expensive drug.


Meet the investigator: Daniel J. Ma, M.D.
Head and neck cancers and stereotactic body radiotherapy are among Dr. Ma's research interests.

Important Links

Comments Comments?
We're interested in your feedback about this email.
Print Edition Want the Print Edition?
A print edition of Forefront is published annually. To request a free subscription, send your name and mailing address to
Mayo Clinic
Cancer Center

13400 E. Shea Blvd.
Scottsdale, AZ 85259

4500 San Pablo Road
Jacksonville, FL 32224

200 First Street SW
Rochester, MN 55905


Newsletter Archive | Contact Mayo Clinic Cancer Center

© 2014 Mayo Foundation for Medical Education and Research,
200 First Street SW, Rochester, MN 55905.
All rights reserved.
Terms of Use